enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD

1.660

-0.010 (-0.60%)

Oct 21, 2026, 11:01 AM EDT - Market open

enGene Therapeutics Financials Overview

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Operating Income	-136.65	-123.17	-62.3	-26.06	-19.43	-15.87
Net Income	-130.36	-117.3	-55.14	-104.74	-29.02	-22.25
Earnings Per Share	-2.02	-2.29	-1.46	-151.22	-44.30	-6.25
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Cash & Investments	266.32	193.74	238.33	81.52	20.43	11.02
Total Debt	33.27	31.8	25.02	9.78	28.32	3.55
Net Cash (Debt)	233.05	161.94	213.31	71.74	-7.89	7.46
Net Cash Growth	36.66%	-24.08%	197.32%	-	-	-
Net Cash Per Share	3.61	3.17	5.65	103.58	-12.04	2.09

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Operating Cash Flow	-103.31	-99.24	-48.28	-24.74	-17.59	-15.98
Capital Expenditures	-0.69	-1.49	-0.93	-0.32	-0.15	-0.25
Free Cash Flow	-104	-100.72	-49.21	-25.06	-17.75	-16.23
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.